Emergence of a Streptococcus pneumoniae clinical isolate highly resistant to telithromycin and fluoroquinolones

Journal of Clinical Microbiology

Volumn 43, Issue 11, 2005, Pages 5800-5803

  Faccone, Diego ^a   Andres, Patricia ^a,b   Galas, Marcelo ^a   Tokumoto, Marta ^b   Rosato, Adriana ^c   Corso, Alejandra ^a  

^a INSTITUTO NACIONAL DE ENFERMEDADES INFECCIOSAS   (Argentina)

^b HOSPITAL UNIVERSITARIO FUNDACIÓN FAVALORO   (Argentina)

^c VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CEFOTAXIME; CEFUROXIME; CHLORAMPHENICOL; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; GATIFLOXACIN; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MACROLIDE; MOXIFLOXACIN; OFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TELITHROMYCIN; TETRACYCLINE; VANCOMYCIN;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATION; BRONCHITIS; CASE REPORT; COMMUNICABLE DISEASE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; REGULATORY MECHANISM; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME;

ADULT; AMINO ACID SEQUENCE; BACTERIAL PROTEINS; BASE SEQUENCE; DEOXYRIBONUCLEASES, TYPE II SITE-SPECIFIC; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ELECTROPHORESIS, GEL, PULSED-FIELD; FEMALE; FLUOROQUINOLONES; HUMANS; KETOLIDES; MOLECULAR SEQUENCE DATA; PNEUMOCOCCAL INFECTIONS; PROTEIN SYNTHESIS INHIBITORS; SEQUENCE ALIGNMENT; STREPTOCOCCUS PNEUMONIAE;

BACTERIA (MICROORGANISMS); STREPTOCOCCUS PNEUMONIAE;

EID: 27744440428     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.43.11.5800-5803.2005     Document Type: Article

References (25)

1. Balfour, J. A., and D. P. Figgitt.2001. Telithromycin. Drugs 61:815-830.
2. Batard, E., M. E. Juvin, C. Jacqueline, D. Bugnon, J. Caillon, G. Potel, and H. B. Drugeon. 2005. Influence of carbon dioxide on the MIC of telithromycin for Streptococcus pneumoniae: an in vitro-in vivo study. Antimicrob. Agents Chemother. 49:464-466.
3. Beekmann, S. E., K. P. Heilmann, S. S. Richter, J. García-de- Lomas, G. V. Doern, and the GRASP Study Group. 2005. Antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and group A β-haemolytic streptococci in 2002-2003 results of the multinational GRASP surveillance program. Int. J. Antimicrob. Agents 25:148-156.
4. Canton, R., M. Morosini, M. C. Enright, and I. Morrissey. 2003. Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Streptococcus pneumoniae: data from the global PROTEKT surveillance programme. J. Antimicrob. Chemother. 52:944-952.
5. Corso, A., E. P. Severina, V. F. Petruk, Y. R. Mauriz, and A. Tomasz. 1998. Molecular characterization of penicillin-resistant Streptococcus pneumoniae isolates causing respiratory disease in the United States. Microb. Drug Resist. 4:325-337.
6. Davies, T. A., L. M. Kelly, M. R. Jacobs, and P. C. Appelbaum. 2000. Antipneumococcal activity of telithromycin by agar dilution, microdilution, E test, and disk diffusion methodologies. J. Clin. Microbiol. 38:1444-1448.
7. Farrel, D. J., S. Douthwaite, I. Morrissey, S. Bakker, J. Poehlsgaard, L. Jakobsen, and D. Felmingham. 2003. Macrolide resistance by ribosomal mutation in clinical isolates of Streptococcus pneumoniae from the PROTEKT 1999-2000 study. Antimicrob. Agents Chemother 47:1777-1783.
8. Farrel, D. J., and D. Felmingham. 2004. Activities of TEL against 13,874 Streptococcus pneumoniae isolates collected between 1999 and 2003. Antimicrob. Agents Chemother. 48:1882-1884.
9. Felmingham, D., R. R. Reinert, Y. Hirakata, and A. Rodloff. 2002. Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and comparative in vitro activity of the ketolide, telithromycin. J. Antimicrob. Chemother. 50(Suppl. 1):25-37.
10. Hortal, M., M. Lovgren, F. de la Hoz, C. I. Agudelo, M. C. Brandileone, T. Camou, S. Casagrande, E. Catañeda, A. Corso, G. Echaniz, J. C. Hormazabal, J. Pace, R. Palacio, G. Perez-Giffoni, R. Ruvinsky, J. L. Di Fabio, and the PAHO SIREVA-Vigia Study Group. 2001. Antibiotic resistance in Streptococcus pneumoniae in six Latin American countries: 1993-1999 surveillance. Microb. Drug Resist. 7:391-401.
11. Kataja, J., H. Seppala, M. Skurnik, H. Sarkkinen, and P. Houvinen. 1998. Different erythromycin resistance mechanisms in group C and group G streptococci. Antimicrob. Agents Chemother. 42:1493-1494.
12. Low, D. E., D. Felmingham, S. D. Brown, M. Rangaraju, and R. Nusrat. 2004. Activity of telithromycin against key pathogens associated with community-acquired respiratory tract infections. J. Infection 49:115-125.
13. McGee, L., L. McDougal, J. Zhou, B. G. Spratt, F. C. Tenover, R. George, R. Hakenbeck, W. Hryniewicz, J. C. Lefévre, A. Tomasz, and K. P. Klugman. 2001. Nomenclature of major antimicrobial-resistant clones of Streptococcus pneumoniae defined by the Pneumococcal Molecular Epidemiology Network. J. Clin. Microbiol. 39:2565-2571.
14. Montanari, M. P., M. Mingoia, I. Cochetti, and P. E. Varaldo. 2003. Phenotypes and genotypes of erythromycin-resistant pneumococci in Italy. J. Clin. Microbiol. 41:428-431.
15. Morosini, M. I., E. Loza, R. del Campo, F. Almaraz, F. Baquero, and R. Cantón. 2003. Fluoroquinolone-resistant Streptococcus pneumoniae in Spain: activities of garenoxacin against clinical isolates including strains with altered topoisomerases. Antimicrob. Agents Chemother. 47:2692-2695.
16. Nagai, K., T. A. Davies, B. E. Dewasse, M. R. Jacobs, and P. C. Appelbaum. 2001. Single- and multi-step resistance selection study of gemifloxacin compared with trovafloxacin, ciprofloxacin, gatifloxacin and moxifloxacin in Streptococcus pneumoniae. J. Antimicrob. Chemother. 48:365-374.
17. National Committee for Clinical Laboratory Standards. 2004. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 6th ed. Approved standard M7-A6. National Committee for Clinical Laboratory Standards. Wayne, Pa.
18. Pan, X., J. Ambler, S. Mehtar, and L. M. Fisher. 1996. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 40:2321-2326.
19. Pérez-Trallero, E., J. M. Marimon, L. Iglesias, and J. Larruskain. 2003. Fluoroquinolone and macrolide treatment failure in pneumococcal pneumonia and selection of multidrug-resistant isolates. Emerg. Infect. Dis. 9:1159-1162.
20. Reinert, R. R. 2004. Clinical efficacy of ketolides in the treatment of respiratory tract infections. J. Antimicrob. Chemother. 53:918-927.
21. Sutclife, J., T. Grebe, A. Tait-Kamradt, and L. Wondrack. 1996. Detection of erythromycin-resistant determinants by PCR. Antimicrob. Agents Chemother. 40:2562-2566.
22. Tait-Kamradt, A., T. Davies, P. C. Appelbaum, F. Depardieu, P. Courvalin, J. Petitpas, L. Wondrack, A. Walker, M. R. Jacobs, and J. Sutcliffe. 2000. Two new mechanisms of macrolide resistance in clinical strains of Streptococcus pneumoniae from Eastern Europe and North America. Antimicrob. Agents Chemother. 44:3395-3401.
23. Tellier, G., M. S. Niederman, R. Nusrat, M. Patel, and B. Lavin. 2004. Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia. J. Antimicrob. Chemother. 54:515-523.
24. Walsh, F., J. Willcock, and S. Amyes. 2003. High-level telithromycin resistance in laboratory-generated mutants of Streptococcus pneumoniae. J. Antimicrob. Chemother. 52:345-353.
25. Walsh, F., F. Carnegy, J. Willcock, and S. Amyes. 2004. Comparative in vitro activity of telithromycin against macrolide-resistant and -susceptible Streptococcus pneumoniae, Moraxella catarrhalis and Haemophilus influenzae. J. Antimicrob. Chemother. 53:793-796.